Search in:

Advanced search

Acta Cardiologica Volume 74, 2019 - Issue 2

Submit an article Journal homepage

132

Views

CrossRef citations to date

Altmetric

Original Scientific Paper

Role of cardiovascular implantable electronic devices in delivering individualized disease-guided management of patients with non-valvular atrial fibrillation and high bleeding risk

Daniel A. N. MascarenhasDrexel University College of Medicine, PA, USA; ;Easton Hospital, Easton, PA, USA; Correspondence[email protected]

Munish SharmaEaston Hospital, Easton, PA, USA;

Paul D. ZieglerMedtronic Diagnostics and Monitoring Research, Mounds View, MN, USA;

Bharat K. KanthariaCardiovascular and Heart Rhythm Consultants, New York, NY, USA

http://orcid.org/0000-0002-4207-0387

Pages 131-139 | Received 09 Jan 2018, Accepted 01 May 2018, Published online: 04 Jun 2018

Cite this article
https://doi.org/10.1080/00015385.2018.1475029
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

References

January CT, Wann LS, Alpert JS, et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071–2104.
PubMed Web of Science ®Google Scholar
Kirchhoff P, Benussi S, Kotecha D, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18:1609–1678.
Web of Science ®Google Scholar
Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–272.
PubMed Web of Science ®Google Scholar
Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest. 2010;138:1093–1100.
PubMed Web of Science ®Google Scholar
Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126:1185–1193.
PubMed Web of Science ®Google Scholar
Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis. 2007;50:433–440.
PubMed Web of Science ®Google Scholar
Vanassche T, Lauw MN, Eikelboom JW, et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J. 2015;36:281–287a.
Web of Science ®Google Scholar
Steinberg BA, Hellkamp AS, Lokhnygina Y, et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J. 2015;36:288–296.
PubMed Web of Science ®Google Scholar
Hunter RJ, McCready J, Diab I, et al. Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death. Heart. 2012;98:48–53.
PubMed Web of Science ®Google Scholar
Bunch TJ, May HT, Bair TL, et al. Atrial fibrillation ablation patients have longterm stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. Heart Rhythm. 2013;10:1272–1277.
PubMed Web of Science ®Google Scholar
Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol. 2009;2:474–480.
PubMed Web of Science ®Google Scholar
Mortensen MB, Fuster V, Muntendam P, et al. A simple disease-guided approach to personalize ACC/AHA-recommended statin allocation in elderly people. J Am Coll Cardiol. 2016;68:881–891.
PubMed Web of Science ®Google Scholar
Mascarenhas DA, Farooq MU, Ziegler PD, et al. Role of insertable cardiac monitors in anticoagulation therapy in patients with atrial fibrillation at high risk of bleeding. Europace. 2016;18:799–806.
Web of Science ®Google Scholar
Winkle RA, Mead RH, Engel G, et al. Discontinuing anticoagulation following successful atrial fibrillation ablation in patients with prior strokes. J Interv Card Electrophysiol. 2013;38:147–153.
PubMed Web of Science ®Google Scholar
Sutton NR, Seth M, Ruwende C, et al. Outcomes of patients with atrial fibrillation undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2016;68:895–904.
Web of Science ®Google Scholar
Al-Khatib SM, Thomas L, Wallentin L, et al. Outcomes of apixaban versus warfarin by type and duration of atrial fibrillation: results from the Aristotle trial. Eur Heart J. 2013;34:2464–2471.
PubMed Web of Science ®Google Scholar
Zimetbaum P, Waks JW, Ellis ER, et al. Role of atrial fibrillation burden in assessing thromboembolic risk. Circ Arrhythm Electrophysiol. 2014;7:1223–1229.
Web of Science ®Google Scholar
Dagres N, Kottkamp H, Piorkowski C, et al. Influence of the duration of Holter monitoring on the detection of arrhythmia recurrences after catheter ablation of atrial fibrillation: implications for patient follow-up. Int J Cardiol. 2010;139:305–306.
Web of Science ®Google Scholar
Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370:2478–2486.
PubMed Web of Science ®Google Scholar
Boriani G, Santini M, Lunati M, et al. Improving thromboprophylaxis using atrial fibrillation diagnostic capabilities in implantable cardioverter-defibrillators: the multicentre Italian ANGELS of AF Project. Circ Cardiovasc Qual Outcomes. 2012;5:182–188.
Web of Science ®Google Scholar
Capucci A, Santini M, Padeletti L, et al. Italian AT500 Registry Investigators. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol. 2005;46:1913–1920.
PubMed Web of Science ®Google Scholar
Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366:120–129.
PubMed Web of Science ®Google Scholar
Van Gelder IC, Healey JS, Crijns HJGM, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J. 2017;38:1339–1344. doi: 10.1093/eurheartj/ehx042
PubMed Web of Science ®Google Scholar
Boriani G, Glotzer TV, Santini M, et al. Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke prevention strategies based on atrial fibrillation information from implanted devices). Eur Heart J. 2014;35:508–516.
PubMed Web of Science ®Google Scholar
Martin DT, Bersohn MM, Waldo AL, et al. IMPACT Investigators. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. Eur Heart J. 2015;36:1660–1668.
PubMed Web of Science ®Google Scholar
Passman R, Leong-Sit P, Andrei A-C, et al. Targeted anticoagulation for atrial fibrillation guided by continuous rhythm assessment with an insertable cardiac monitor: The Rhythm Evaluation for Anticoagulation with Continuous Monitoring (REACT.COM) Pilot Study. J Cardiovasc Electrophysiol. 2016;27:264–270.
PubMed Web of Science ®Google Scholar
Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace. 2011;13:723–746.
PubMed Web of Science ®Google Scholar
Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–1833.
PubMed Web of Science ®Google Scholar
Martin-Doyle W, Essebag V, Zimetbaum P, et al. Trends in US hospitalization rates and rhythm control therapies following publication of the AFFIRM and RACE trials. J Cardiovasc Electrophysiol. 2011;22:548–553.
Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.

Novartis. Your partner in Heart Failure & Atherosclerosis >>

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Role of cardiovascular implantable electronic devices in delivering individualized disease-guided management of patients with non-valvular atrial fibrillation and high bleeding risk

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Role of cardiovascular implantable electronic devices in delivering individualized disease-guided management of patients with non-valvular atrial fibrillation and high bleeding risk

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date